Clene to Participate in a Panel Discussion at the Maxim Growth Summit

Rhea-AI Summary

Clene (Nasdaq: CLNN) said management will participate in a panel discussion at the Maxim Growth Summit and will host 1x1 investor meetings on October 22, 2025 in New York City. The panel is titled Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories. Meeting requests for 1x1 sessions are available through a Maxim representative.

The company and its subsidiary Clene Nanomedicine focus on mitochondrial health and neuronal protection for diseases including ALS and MS.

SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a panel discussion at the Maxim Growth Summit and host 1x1 investor meetings.

Date: October 22, 2025
Location: New York City, NY
Panel Discussion: Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories
1x1 Meetings: Please contact your Maxim representative

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856

FAQ

When will Clene (CLNN) participate in the Maxim Growth Summit?

Clene management will participate on October 22, 2025 in New York City.

What panel will Clene (CLNN) join at the Maxim Growth Summit?

Clene will join the Neurodegenerative Diseases Panel – Under the Radar Innovators session.

How can investors request 1x1 meetings with Clene (CLNN) at the Maxim Growth Summit?

Investors should contact their Maxim representative to request 1x1 meetings.

Which Clene subsidiaries are referenced for the Maxim Growth Summit appearance?

The announcement references Clene and its wholly owned subsidiary Clene Nanomedicine.

What therapeutic areas will Clene (CLNN) highlight at the panel on October 22, 2025?

Clene will focus on mitochondrial health and neuronal protection for ALS and MS.

Where is the Maxim Growth Summit session featuring Clene (CLNN) located?

The session will take place in New York City, NY on October 22, 2025.